| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Bruce D Walker | Q88402236 |
| P2093 | author name string | Gaurav D Gaiha | |
| David R Collins | |||
| P2860 | cites work | Design and pre-clinical evaluation of a universal HIV-1 vaccine | Q21092234 |
| CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract | Q22242965 | ||
| Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract | Q22242981 | ||
| HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors | Q24676982 | ||
| Cytomegalovirus Infection and Memory T Cell Inflation | Q26786776 | ||
| Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS | Q28215577 | ||
| Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial | Q28972526 | ||
| The major genetic determinants of HIV-1 control affect HLA class I peptide presentation | Q29417018 | ||
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| A whole-genome association study of major determinants for host control of HIV-1 | Q29614891 | ||
| Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group | Q29614934 | ||
| Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation | Q29615068 | ||
| HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells | Q29616205 | ||
| Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes | Q29616210 | ||
| PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression | Q29618956 | ||
| Evolutionary and immunological implications of contemporary HIV-1 variation. | Q30329205 | ||
| Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine | Q30578618 | ||
| HIV-1 group M conserved elements vaccine | Q33308246 | ||
| Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study | Q33395678 | ||
| Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control | Q33594461 | ||
| Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables | Q33614495 | ||
| Highly divergent patterns of genetic diversity and evolution in proviral quasispecies from HIV controllers | Q33630471 | ||
| Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy | Q33648533 | ||
| Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys | Q33712291 | ||
| Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys | Q33712578 | ||
| HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers | Q37127920 | ||
| Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control | Q37169129 | ||
| Influence of HLA-C expression level on HIV control | Q37200459 | ||
| Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies | Q37246321 | ||
| Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity | Q37262408 | ||
| Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection | Q37273158 | ||
| Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection | Q37273289 | ||
| Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge | Q37287080 | ||
| Efficiency of cell-free and cell-associated virus in mucosal transmission of human immunodeficiency virus type 1 and simian immunodeficiency virus | Q37336708 | ||
| In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit | Q37381314 | ||
| Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. | Q37410726 | ||
| CD8+ T cells from HLA-B*57 elite suppressors effectively suppress replication of HIV-1 escape mutants | Q37427587 | ||
| Vaccine-induced CD8+ T cells control AIDS virus replication | Q37442789 | ||
| Simian Immunodeficiency Virus-Producing Cells in Follicles Are Partially Suppressed by CD8+ Cells In Vivo | Q37448333 | ||
| Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys | Q37486401 | ||
| Both HLA-B*57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers | Q37547677 | ||
| Dynamics of SIV-specific CXCR5+ CD8 T cells during chronic SIV infection. | Q37682298 | ||
| A systematic review of definitions of extreme phenotypes of HIV control and progression | Q38154750 | ||
| Multiple Origins of Virus Persistence during Natural Control of HIV Infection | Q38379102 | ||
| Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study | Q38477498 | ||
| Tissue-resident memory T cells: local specialists in immune defence. | Q38674833 | ||
| Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda | Q38885289 | ||
| T-Cell Receptor (TCR) Clonotype-Specific Differences in Inhibitory Activity of HIV-1 Cytotoxic T-Cell Clones Is Not Mediated by TCR Alone. | Q39026157 | ||
| Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. | Q39112993 | ||
| Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand | Q39358681 | ||
| Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. | Q39362365 | ||
| Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice | Q39407795 | ||
| Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection | Q40088529 | ||
| HIV-1 epitopes presented by MHC class I types associated with superior immune containment of viremia have highly constrained fitness landscapes | Q40101982 | ||
| Demographics and natural history of HIV-1-infected spontaneous controllers of viremia | Q40291456 | ||
| Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial | Q40332276 | ||
| Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies | Q40366328 | ||
| Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection | Q40584352 | ||
| CXCR5(+) follicular cytotoxic T cells control viral infection in B cell follicles | Q40589864 | ||
| Elite controller CD8+ T cells exhibit comparable viral inhibition capacity, but better sustained effector properties compared to chronic progressors | Q40615883 | ||
| Early antibody therapy can induce long-lasting immunity to SHIV | Q33762877 | ||
| Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller | Q33786447 | ||
| Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. | Q33839450 | ||
| Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection | Q33869806 | ||
| Impaired replication capacity of acute/early viruses in persons who become HIV controllers | Q33963989 | ||
| Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. | Q34056087 | ||
| Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers | Q34083315 | ||
| Copy number variation of KIR genes influences HIV-1 control | Q34090869 | ||
| A high-throughput single-cell analysis of human CD8⁺ T cell functions reveals discordance for cytokine secretion and cytolysis | Q34220876 | ||
| Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies | Q34229664 | ||
| Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma | Q34332166 | ||
| Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design | Q34334803 | ||
| HIV-1 DNA predicts disease progression and post-treatment virological control | Q34350410 | ||
| Immune clearance of highly pathogenic SIV infection | Q34370314 | ||
| HIV-1 continues to replicate and evolve in patients with natural control of HIV infection | Q34416428 | ||
| Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control | Q34435052 | ||
| Prolonged control of an HIV type 1 escape variant following treatment interruption in an HLA-B*27-positive patient | Q34447772 | ||
| Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. | Q34468117 | ||
| Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus | Q34468698 | ||
| Intranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trial | Q34513477 | ||
| Compartmentalization of simian immunodeficiency virus replication within secondary lymphoid tissues of rhesus macaques is linked to disease stage and inversely related to localization of virus-specific CTL. | Q34550802 | ||
| Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction | Q34570127 | ||
| PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection | Q34570624 | ||
| Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study | Q34629153 | ||
| A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication | Q34646987 | ||
| Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy | Q34647680 | ||
| Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial | Q34648825 | ||
| Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor | Q34780395 | ||
| Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients | Q34874985 | ||
| Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection | Q34994754 | ||
| Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine | Q35009558 | ||
| B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers | Q35058635 | ||
| Reduction of CD4+ T cells in vivo does not affect virus load in macaque elite controllers | Q35077809 | ||
| Coordinate linkage of HIV evolution reveals regions of immunological vulnerability | Q35105172 | ||
| Structural topology defines protective CD8+ T cell epitopes in the HIV proteome | Q91711152 | ||
| Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study) | Q91944005 | ||
| A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge | Q91967570 | ||
| Elite control of HIV is associated with distinct functional and transcriptional signatures in lymphoid tissue CD8+ T cells | Q92094111 | ||
| HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation | Q92144268 | ||
| Early evidence of inactivated enterovirus 71 vaccine impact against hand, foot, and mouth disease in a major center of ongoing transmission in China, 2011-2018: a longitudinal surveillance study | Q92268500 | ||
| Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers | Q92312862 | ||
| Possible clearance of transfusion-acquired nef/LTR-deleted attenuated HIV-1 infection by an elite controller with CCR5 Δ32 heterozygous and HLA-B57 genotype | Q92702651 | ||
| Lessons for general vaccinology research from attempts to develop an HIV vaccine | Q93063721 | ||
| Escape from highly effective public CD8+ T-cell clonotypes by HIV | Q35182712 | ||
| Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infection | Q35241486 | ||
| Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations | Q35521811 | ||
| Immunology. Immune activation with HIV vaccines | Q35551760 | ||
| Beyond adjuvants: immunomodulation strategies to enhance T cell immunity | Q35666506 | ||
| HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype | Q35749755 | ||
| Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication | Q35785115 | ||
| CD8(+) T-cell Cytotoxic Capacity Associated with Human Immunodeficiency Virus-1 Control Can Be Mediated through Various Epitopes and Human Leukocyte Antigen Types | Q35797743 | ||
| Definition of the viral targets of protective HIV-1-specific T cell responses | Q35800157 | ||
| HLA B*5701-positive long-term nonprogressors/elite controllers are not distinguished from progressors by the clonal composition of HIV-specific CD8+ T cells | Q35826897 | ||
| Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. | Q35867686 | ||
| Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control | Q35888710 | ||
| Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression | Q35904453 | ||
| Differential Impact of In Vivo CD8+ T Lymphocyte Depletion in Controller versus Progressor Simian Immunodeficiency Virus-Infected Macaques. | Q35913945 | ||
| Comprehensive analysis of unique cases with extraordinary control over HIV replication | Q36010191 | ||
| Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding | Q36172128 | ||
| The Breadth of Expandable Memory CD8+ T Cells Inversely Correlates with Residual Viral Loads in HIV Elite Controllers | Q36208223 | ||
| Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations | Q36238124 | ||
| Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. | Q36368095 | ||
| A vaccine strategy that protects against genital herpes by establishing local memory T cells | Q36403540 | ||
| Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy | Q36498230 | ||
| TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection | Q36513955 | ||
| Recent developments in the effort to cure HIV infection: going beyond N = 1. | Q36515170 | ||
| Host factors dictate control of viral replication in two HIV-1 controller/chronic progressor transmission pairs | Q36547178 | ||
| Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production | Q36547664 | ||
| Broadly targeted CD8⁺ T cell responses restricted by major histocompatibility complex E. | Q36624194 | ||
| Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells | Q36745227 | ||
| HIV-1 conserved-element vaccines: relationship between sequence conservation and replicative capacity | Q36827382 | ||
| Relative rate and location of intra-host HIV evolution to evade cellular immunity are predictable | Q36933059 | ||
| Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection | Q36951283 | ||
| Impact of pre-adapted HIV transmission. | Q36984267 | ||
| Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation | Q37002564 | ||
| Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control | Q37054526 | ||
| Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery | Q37070349 | ||
| PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals | Q40653907 | ||
| Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers | Q40659603 | ||
| Dysfunctional HIV-specific CD8+ T cell proliferation is associated with increased caspase-8 activity and mediated by necroptosis | Q41590197 | ||
| Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. | Q41827503 | ||
| Primary CD8+ T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4+ T cells | Q41915015 | ||
| Evaluating the impact of functional genetic variation on HIV-1 control | Q41926563 | ||
| Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load | Q42205079 | ||
| Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters | Q43070781 | ||
| Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection | Q43542210 | ||
| CXCR5+ CCR7- CD8 T cells are early effector memory cells that infiltrate tonsil B cell follicles | Q44152856 | ||
| Therapeutic dendritic-cell vaccine for chronic HIV-1 infection | Q45165349 | ||
| Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors | Q45741753 | ||
| Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells | Q47199883 | ||
| Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment | Q47307973 | ||
| Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. | Q47349491 | ||
| Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption | Q47553711 | ||
| Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals | Q47555195 | ||
| Induction of vaginal-resident HIV-specific CD8 T cells with mucosal prime-boost immunization | Q47601205 | ||
| HIV-Specific CD8+ T Cells Exhibit Reduced and Differentially Regulated Cytolytic Activity in Lymphoid Tissue. | Q49748869 | ||
| T cell receptors for the HIV KK10 epitope from patients with differential immunologic control are functionally indistinguishable. | Q50043370 | ||
| HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. | Q51320237 | ||
| The Global HIV Epidemic: What Will It Take to Get to the Finish Line? | Q51784351 | ||
| Viral Characteristics Associated with the Clinical Nonprogressor Phenotype Are Inherited by Viruses from a Cluster of HIV-1 Elite Controllers. | Q52325888 | ||
| EFFECT OF SHORT-TERM ART INTERRUPTION ON LEVELS OF INTEGRATED HIV DNA. | Q52624999 | ||
| CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue. | Q53551795 | ||
| Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) | Q56911184 | ||
| Phase I clinical trial of an intranodally administered mRNA based therapeutic vaccine against HIV-1 infection | Q57023723 | ||
| Identification and characterization of HIV-specific resident memory CD8 + T cells in human lymphoid tissue | Q57225626 | ||
| Genomewide Association Study of an AIDS‐Nonprogression Cohort Emphasizes the Role Played byHLAGenes (ANRS Genomewide Association Study 02) | Q57249723 | ||
| CD8+ T-cell responses to different HIV proteins have discordant associations with viral load | Q57259602 | ||
| Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes | Q57916541 | ||
| Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial | Q58587972 | ||
| Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV | Q59125545 | ||
| Long-term remission despite clonal expansion of replication-competent HIV-1 isolates | Q59134950 | ||
| First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1 | Q59351069 | ||
| Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound | Q59355095 | ||
| HIV-1 latent reservoir size and diversity are stable following brief treatment interruption | Q59358567 | ||
| HIV Controllers Exhibit Effective CD8 T Cell Recognition of HIV-1-Infected Non-activated CD4 T Cells | Q64083948 | ||
| Polymorphism at the HLA-E locus predates most HLA-A and -B polymorphism | Q68184420 | ||
| Frequency and function of HIV-specific CD8(+) T cells | Q74608670 | ||
| HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors | Q78342521 | ||
| PD-1 Blockade and TLR7 Activation Lack Therapeutic Benefit in Chronic Simian Immunodeficiency Virus-Infected Macaques on Antiretroviral Therapy | Q90000752 | ||
| Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology | Q90265999 | ||
| Accelerating HIV vaccine development using non-human primate models | Q90334537 | ||
| HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers | Q90340957 | ||
| The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies | Q90808810 | ||
| HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable | Q90980677 | ||
| A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses | Q91044500 | ||
| Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial | Q91360476 | ||
| Strong TH1-biased CD4 T cell responses are associated with diminished SIV vaccine efficacy | Q91360501 | ||
| Topological perspective on HIV escape | Q91711007 | ||
| P921 | main subject | CD8-positive T-lymphocytes | Q70192767 |
| P577 | publication date | 2020-02-12 | |
| 2020-08-01 | |||
| P1433 | published in | Nature Reviews Immunology | Q43355 |
| P1476 | title | CD8+ T cells in HIV control, cure and prevention |
Search more.